Expert Ratings for Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) has received mostly bullish ratings from analysts in the last quarter, with 7 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target for the company has increased by 6.15% to $213.89.
August 10, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals has received mostly positive ratings from analysts, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The predominantly bullish ratings for Jazz Pharmaceuticals indicate a positive outlook for the company, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100